Redwood City, CA (April 26, 2011) – EndoGastric Solutions (EGS), the leader in the emerging field of Natural Orifice Surgery (NOS), today announced that the American Society of General Surgeons (ASGS) recently issued a position statement in support of transoral fundoplication for the surgical treatment of gastroesophageal reflex disease (GERD).
“The ASGS believes that there is a sufficient body of peer-reviewed literature that establishes transoral fundoplication as reasonable and medically necessary for a subset of patients who are candidates for surgical fundoplication,” said Guy Nicastri, M.D., ASGS President. According to the ASGS statement, General Surgeons have a choice on how to achieve a surgical fundoplication – open incisional, laparoscopic or transoral. “The ASGS believes that in patients who are candidates for fundoplication, the preferred surgical technique for creating the fundoplication should be left to the discretion of the General Surgeon and should be based on the surgeon’s independent medical judgment and the individual patient’s clinical circumstances.”
“We are very pleased that the ASGS has issued a favorable statement supporting the medical necessity of transoral fundoplication,” said Thierry Thaure, President and Chief Executive Officer of EndoGastric Solutions. “Over the past two years, GERD specialists have added transoral fundoplication to their continuum of care. The growing body of evidence in clinical practice and peer-reviewed literature, along with the ASGS 2011 Position Statement, will help us communicate with payors that it is time to update their policies to include transoral fundoplication as an acceptable technique for creating a surgical fundoplication by trained General Surgeons.”
The transoral fundoplication is a surgical procedure performed through the mouth for the treatment of GERD; it employs EndoGastric Solutions’ EsophyX device. Transoral fundoplication fills the treatment gap that exists between pharmaceutical therapy and more invasive surgical fundoplications, addressing a population estimated at over 14 million. To date, clinical results have been approaching those achieved by more invasive surgical techniques.
The ASGS position statement is available here.
About EsophyX® and Transoral Incisionless Fundoplication (TIF®)
The EsophyX device was FDA cleared in 2007, and is commercially available in the United States. Inserted transorally with visual guidance from an endoscope, the EsophyX device is used in the TIF procedure to reconstruct the gastroesophageal valve (GEV), restoring its competency and reestablishing the barrier to reflux. TIF is a surgical solution that corrects the root cause of Gastroesophageal Reflux Disease (GERD), a disease that affects over 60 million people in the U.S. Because TIF is rooted in traditional surgical principles and is minimally invasive, the procedure offers similar effectiveness to a surgical repair with the safety profile of a transoral approach. To date, more than 10,000 patients have been treated worldwide.
About EndoGastric Solutions®
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), headquartered in Redwood City, California, is a leader in the endoluminal treatment of digestive diseases. EGS’ mission is to utilize the most current wisdom in gastroenterology and surgery to develop procedures and products that address unmet needs in gastrointestinal diseases.